Advancing Novel Therapeutics With End-To-End Lipid Nanoparticle Development And Manufacturing

By Natalia Zisman, Senior Manager, Technical Marketing, Evonik

Lipid nanoparticles (LNPs) are crucial to the successful delivery of mRNA vaccines and other RNA and nucleic acid therapeutics. Developers of these novel products need the support of a collaborative partner such as Evonik with extensive experience working with all type of drug substances, lipids, lipid formulations, and lipid production methods. An effective partner must also possess the necessary unique analytical capabilities for LNP characterization and the ability to support clients from concept to commercialization.

In this article, explore the following topics:

• The Importance of LNPs for mRNA Therapies
• Pathway to Approval
• Conventional Liposomes vs. Nucleic Acid LNPs
• Bringing a Breadth of Lipid Nanoparticle Knowledge and Capabilities to the Table
• Future Opportunities for Lipid Delivery
• Supporting the Entire Value Chain